Compare JMS Co., Ltd. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROCE of 1.90%
- The company has been able to generate a Return on Capital Employed (avg) of 1.90% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
3
Poor long term growth as Net Sales has grown by an annual rate of 2.73% over the last 5 years
4
Risky -
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 10,858 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.40
-0.75%
0.26
Revenue and Profits:
Net Sales:
16,870 Million
(Quarterly Results - Mar 2026)
Net Profit:
-670 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.77%
0%
2.77%
6 Months
0%
0%
0.0%
1 Year
3.73%
0%
3.73%
2 Years
-18.2%
0%
-18.2%
3 Years
-23.14%
0%
-23.14%
4 Years
-21.52%
0%
-21.52%
5 Years
-46.77%
0%
-46.77%
JMS Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.73%
EBIT Growth (5y)
-37.22%
EBIT to Interest (avg)
4.79
Debt to EBITDA (avg)
3.23
Net Debt to Equity (avg)
0.43
Sales to Capital Employed (avg)
1.03
Tax Ratio
98.75%
Dividend Payout Ratio
467.91%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
1.90%
ROE (avg)
1.39%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.26
EV to EBIT
114.18
EV to EBITDA
6.85
EV to Capital Employed
0.47
EV to Sales
0.42
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
0.42%
ROE (Latest)
-0.75%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
16,870.00
17,114.00
-1.43%
Operating Profit (PBDIT) excl Other Income
1,183.00
1,017.00
16.32%
Interest
123.00
91.00
35.16%
Exceptional Items
-1,010.00
0.00
Consolidate Net Profit
-670.00
-166.00
-303.61%
Operating Profit Margin (Excl OI)
11.50%
3.20%
0.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is -1.43% vs -0.83% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -303.61% vs -84.44% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'26
Mar'26
Mar'25
Change(%)
Net Sales
65,845.00
69,749.00
-5.60%
Operating Profit (PBDIT) excl Other Income
4,216.00
4,762.00
-11.47%
Interest
407.00
340.00
19.71%
Exceptional Items
-1,010.00
0.00
Consolidate Net Profit
-819.00
7.00
-11,800.00%
Operating Profit Margin (Excl OI)
5.80%
12.50%
-0.67%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2026 is -5.60% vs 6.83% in Mar 2025
Consolidated Net Profit
YoY Growth in year ended Mar 2026 is -11,800.00% vs 115.56% in Mar 2025
About JMS Co., Ltd. 
JMS Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






